Sunday, January 08, 2023 9:14:47 PM
Hey There,
The evolution of a pure royalty company starts with the discovery of a resource , whether it be a natural resource, intellectual property or.......! The company develops the resource for marketing and sales or leasing etc. etc. At some point in the future when demand exceeds the discovery company's ability to scale, a much larger, fully integrated company will buy the discovery company and part of the acquisition cost is a royalty or percentage of each "unit" sold that is retained by the selling company. In the case of Northwest, the company could sell DCVax-l for cash and a royalty on all future sales, both as a single treatment and in combination. For all other large tumor cancers, the company would simply sell the rights to manufacture, market and sell the vaccines and retain a royalty as before. This strategy eliminates the waste of redundancy, reduces the costs to patients from the economies of scale and the entire healthcare world ends up with the "winning ticket" !!!
AND EVERYONE GETS TO STAY IN THE GAME AND SHARE IN FUTURE PROFITS!!!
Very sweet deal!!!
Cheers,
BB
The evolution of a pure royalty company starts with the discovery of a resource , whether it be a natural resource, intellectual property or.......! The company develops the resource for marketing and sales or leasing etc. etc. At some point in the future when demand exceeds the discovery company's ability to scale, a much larger, fully integrated company will buy the discovery company and part of the acquisition cost is a royalty or percentage of each "unit" sold that is retained by the selling company. In the case of Northwest, the company could sell DCVax-l for cash and a royalty on all future sales, both as a single treatment and in combination. For all other large tumor cancers, the company would simply sell the rights to manufacture, market and sell the vaccines and retain a royalty as before. This strategy eliminates the waste of redundancy, reduces the costs to patients from the economies of scale and the entire healthcare world ends up with the "winning ticket" !!!
AND EVERYONE GETS TO STAY IN THE GAME AND SHARE IN FUTURE PROFITS!!!
Very sweet deal!!!
Cheers,
BB
Recent NWBO News
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
